CRISPR Therapeutics AG · NASDAQ:CRSP

CRISPR Therapeutics — Investor Presentation (May 2024)

26 slides from CRISPR Therapeutics's investor presentation, May 2024

  1. Slide 1: Creating transformative gene-based medicines for serious diseases

    Creating transformative gene-based medicines for serious diseases Corporate Overview Q2 2024 © 2024 CRISPR Therapeutics | 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about any or all of th

  3. Slide 3: CRISPR Therapeutics Highlights

    CRISPR Therapeutics Highlights Leading gene editing company with a strong and diversified pipeline, efficient operating model, and proven track record of execution Best-in-class technology, strategy, and execution culminating Hemoglobinopathies in the historic approval of CASGEVY Advancing multiple

  4. Slide 4: Broad and Diversified Pipeline

    Broad and Diversified Pipeline Program Disease Research IND-enabling Clinical Approved Partner Structure Severe sickle cell disease (SCD) CASGEVY1 Collaboration Transfusion-dependent β-thalassemia (TDT) Heme Next-generation conditioning Various Wholly owned2 In vivo editing of HSCs Various Wholly ow

  5. Slide 5: CASGEVY: Historic First Approval of a CRISPR-Based Medicine

    CASGEVY: Historic First Approval of a CRISPR-Based Medicine Unparalleled speed and execution Well-positioned for commercial success to a landmark approval1 Strong commercial partner with Vertex Foundational Year in 2024 Significant Robust support market ex-U.S., from the U.S. including in the ecosys

  6. Slide 6: Groundbreaking Data Across >95 Patients

    Groundbreaking Data Across >95 Patients TDT: Transfusion independence achieved out to 45 months SCD: VOC-free and no in-patient hospitalizations for VOCs achieved out to 45.5 months Locatelli et al. NEJM 2024 Frangoul et al. NEJM 2024 Exa-cel treatment resulted in early and sustained increases in Hb

  7. Slide 7: CASGEVY has a Large Addressable Market

    CASGEVY has a Large Addressable Market Significant opportunity in US and Europe, with potential to expand further with targeted conditioning β-thalassemia Sickle Cell Disease Exa-cel addressable market with 5,000 standard of care conditioning 30,000 Exa-cel potential market with 16,000+ targeted con

  8. Slide 8: Expanding the Patient Population that can Benefit

    Expanding the Patient Population that can Benefit Near Term: Targeted conditioning using Antibody-drug conjugate against cKit to expand addressable population for CASGEVY High on-target potency Proprietary GMP monoclonal antibody Optimal attributes with short half-life targeting cKit Low off-target

  9. Slide 9: Three Additional Franchises Beyond CASGEVY

    Three Additional Franchises Beyond CASGEVY CAR-T In Vivo Type 1 Diabetes I/O and Autoimmune Common and Rare Disease World’s most Established sophisticated CAR T First-in-class edited mRNA-LNP cell candidates, beta cell therapies platform for manufactured for T1D liver editing internally Multiple opp

  10. Slide 10: Our Gene-Edited Allogeneic CAR T Franchise

    Our Gene-Edited Allogeneic CAR T Franchise Advancing the most sophisticated CAR T cell candidates in the clinic against multiple opportunities across heme and solid cancers, plus autoimmune indications First-generation: CTX110 and CTX130 Next-generation: CTX112 and CTX131 Additional indications and

  11. Slide 11: CTX112 and CTX131 Incorporate Novel Potency Edits

    CTX112 and CTX131 Incorporate Novel Potency Edits Next-generation CRISPR gene-edited allogeneic CAR T chassis TGFBR2 CAR Novel Potency Edits disruption TCR MHC I disruption • Regnase-1 KO: Increase disruption • TCR KO: Prevent GvHD functional persistence, • CAR KI: Site-specific cytokine secretion a

  12. Slide 12: CTX112 and CTX131 Build Upon First Gen CAR T's in Oncology

    CTX112 and CTX131 Build Upon First Gen CAR T's in Oncology First-generation CAR Ts, CTX110 & CTX130 Demonstrate proof-of-concept that allogeneic CAR T cells can produce durable remissions following a standard LD regimen in hematological malignancies as well as solid tumors Potency edits in CTX112 le

  13. Slide 13: CTX112 and CTX131 Clinical Trials

    CTX112 and CTX131 Clinical Trials Phase 1/2 safety and efficacy Phase 1/2 safety and efficacy study evaluating CTX112 study evaluating CTX131 ▪ Relapsed or refractory B-cell ▪ Relapsed or refractory solid tumors malignancies starting with renal cell carcinoma (RCC) Indications ▪ Expanding into autoi

  14. Slide 14: Expanding CTX112 into Autoimmune Disease

    Expanding CTX112 into Autoimmune Disease CTX112 has a significant opportunity in autoimmune diseases B cell depletion following CTX110 infusion among patients with detectable B cells at baseline (N=9) ▪ Allogeneic CAR T cells produce deep B cell depletion 1000 in B cell malignancies, as observed wit

  15. Slide 15: CTX112 is Differentiated from Other CD19 Therapies

    CTX112 is Differentiated from Other CD19 Therapies Autologous CD19 Other Allo. T or CTX112 CAR Ts NK cells T-cell engagers mAbs or ADCs Safety Site specific CAR Reduced risk of accumulated AEs with chronic dosing insertion Efficacy More potency w/ next- Deeper depletion of B-cells gen edits Ability

  16. Slide 16: Owning Manufacturing Gives Us Flexibility

    Owning Manufacturing Gives Us Flexibility Manufacturing CTX112 and CTX131 at our internal GMP facility These candidates exhibit increased manufacturing robustness, with a higher and more consistent number of CAR T cells produced per batch Potential for significantly lower COGS and greater scalabilit

  17. Slide 17: Advancing Plug-and-Play In Vivo Platform Across Multiple Diseases

    Advancing Plug-and-Play In Vivo Platform Across Multiple Diseases Established plug-and-play LNP/ Potential to transform the treatment Advancing in vivo programs in mRNA platform for in vivo gene paradigm for CVD with additional rare diseases disruption, starting in the liver CTX310, CTX320, CTX330 a

  18. Slide 18: CTX310 and CTX320 Could Transform the Treatment Paradigm for ASCVD

    CTX310 and CTX320 Could Transform the Treatment Paradigm for ASCVD The chronic care model A new treatment paradigm: one-time Daily Weekly Multiple infusions Surgical CRISPR-based therapies with the potential to… medications injections annually interventions Recapitulate the proven benefit of targets

  19. Slide 19: CTX310 and CTX320: A One-Time Dose to Treat CVD

    CTX310 and CTX320: A One-Time Dose to Treat CVD Intravenous delivery Reduced atherogenic CRISPR/Cas9-based editing targeting the liver lipoprotein concentrations CTX310 or CTX320 Endothelial lipase LDL-C ANGPTL3 Endocytosis and TG (CTX310) Lipoprotein lipase Endosomal escape Lp(a) DNA cleavage (CTX3

  20. Slide 20: CTX310 Targeting ANGPTL3 for Cardiovascular Disease

    CTX310 Targeting ANGPTL3 for Cardiovascular Disease Natural loss-of-function mutations in ANGPTL3 are associated A one-time, CRISPR-based therapy could recapitulate the with reduced LDL-C, triglycerides (TG), and ASCVD risk protective effect of naturally occurring loss-of-function without any negati

  21. Slide 21: CTX320 Targeting Lp(a), an Independent Risk Factor for ASCVD

    CTX320 Targeting Lp(a), an Independent Risk Factor for ASCVD Elevated lipoprotein(a) [Lp(a)] levels Up to 20% of the global population A one-time, CRISPR-based therapy increase ASCVD risk, as observed has elevated Lp(a)6,7, primarily could recapitulate the protective across numerous studies1,2,3,4,5

  22. Slide 22: Three Parallel Efforts in Type 1 Diabetes (T1D)

    Three Parallel Efforts in Type 1 Diabetes (T1D) Gene editing is key to achieving the goal of developing a beta-cell replacement product to treat diabetes without requiring long-term immunosuppression 1 2 3 CTX211 (formerly VCTX211) Deviceless approach Non-exclusive license with Vertex First-in-class

  23. Slide 23: Next-Generation Editing: Poised to Continue Our Leading Role

    Next-Generation Editing: Poised to Continue Our Leading Role The race to bring next-generation Both editing and delivery expertise No one editing approach will gene-editing technologies to the needed to make the required edit dominate – each disease will clinic has just begun in the required locatio

  24. Slide 24: Strong U.S. and Global Foundational IP Position

    Strong U.S. and Global Foundational IP Position United States Europe and Global CVC granted patents of broad scope; CVC granted foundational patents, multiple applications progressing including use in eukaryotes Patents of broad scope granted in the EU, Canada, China, 56 Patents of broad scope grant

  25. Slide 25: Several Upcoming Catalysts Across Portfolio

    Several Upcoming Catalysts Across Portfolio Program Disease Status Heme CASGEVY SCD and TDT Ongoing launch – 2024 is a foundational year B-cell malignancies Trial ongoing – data update in 2024 CTX112 - allo CD19 CAR-T Autoimmune SLE Trial on track to be initiated 1H 2024 I/O & Solid tumors Trial in

  26. Slide 26: Building an Industry-Leading Company

    Building an Industry-Leading Company BEST-IN-CLASS COLLABORATIVE & EXPERIENCED platform and ENTREPRENEURIAL management team capabilities culture INTERNAL ~$2.1 BILLION MANUFACTURING cash balance as of at state-of-the-art March 31, 2024 GMP facility CRISPR Therapeutics | www.crisprtx.com © 2024 CRISP

CRISPR Therapeutics — Investor Presentation (May 2024) on 6ix